Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies

Warren, Annabelle M.; Knudsen, Søren Tang; Cooper, Mark E.

doi:10.1080/14728222.2019.1624721

Cited by 178 publications

(145 citation statements)

References 145 publications

Supporting

Mentioning

143

Contrasting

Order By: Relevance

“…Employing a nested case–control study design, Wong et al studied the predictive value of serum baseline levels of two promising biomarkers, transforming growth factor‐β1 (TGF‐β1) and bone morphogenic protein‐7 (BMP‐7), both secretory cytokines belonging to the TGF‐β superfamily, for the subsequent development of major renal endpoints . TGF‐β1 is considered the primary driver of tissue fibrosis development in both diabetic and non‐diabetic kidney disease, whereas BMP‐7 is a natural TGF‐β1 antagonist that is lost in kidney tubuli in progressive diabetic kidney disease and is considered protective against kidney fibrosis development.…”

Section: Biomarker Studies On the Advance Populationmentioning

confidence: 99%

“…In another nested case–control sub‐study on the ADVANCE population, Thomas et al examined the association of baseline serum levels of advanced glycation end products (AGEs) and their receptor (RAGE) with all‐cause mortality, cardiovascular events, and new or worsening nephropathy. AGEs represent long‐lasting post‐translational molecular modifications induced by hyperglycaemia that are involved in the development of late complications in diabetes mellitus, and may constitute part of the explanation for the “legacy effect” of poor glycaemic control over years or even decades …”

Section: Biomarker Studies On the Advance Populationmentioning

confidence: 99%

“…Hence, the study indicates a predictive value of these biomarkers for future micro‐ and macrovascular events. Indeed, these molecular pathways have been explored as pharmacological targets for the prevention of late diabetic complications in animal and human studies …”

Section: Biomarker Studies On the Advance Populationmentioning

confidence: 99%

“…Indeed, these molecular pathways have been explored as pharmacological targets for the prevention of late diabetic complications in animal and human studies. 27…”

Section: Biomarker Studies On the Advance Populationmentioning

confidence: 99%

See 3 more Smart Citations

Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?

Knudsen

Cooper

2020

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial was a landmark randomized controlled clinical trial in 11 140 type 2 diabetic patients from 215 centers in 20 countries with a two‐by‐two factorial design. In the blood pressure‐lowering arm, patients were treated using a fixed combination of the ACE‐inhibitor, perindopril, and the thiazide‐like diuretic, indapamide, or placebo, whereas in the glucose‐lowering arm, the intervention compared the sulphonylurea gliclazide plus other glucose‐lowering drugs, targeting a glycated hemoglobin value of 6.5% or less, with standard glucose control. Primary end‐points were major macro‐ and microvascular events in both arms. This review gives an overview of the results of the primary randomized trial, results from observational follow‐up studies, and results of several biomarker studies and discusses the perspectives of these data in the context of recent major outcome trials for current medical treatment.

show abstract

Section: Biomarker Studies On the Advance Populationmentioning

confidence: 99%

Section: Biomarker Studies On the Advance Populationmentioning

confidence: 99%

Section: Biomarker Studies On the Advance Populationmentioning

confidence: 99%

“…Indeed, these molecular pathways have been explored as pharmacological targets for the prevention of late diabetic complications in animal and human studies. 27…”

Section: Biomarker Studies On the Advance Populationmentioning

confidence: 99%

See 2 more Smart Citations

Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?

Knudsen

Cooper

2020

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…Diabetic nephropathy (DN) is a widely recognized microvascular complication of diabetes and the largest single cause of the end-stage renal disease (ESRD), which is still a major contributor to morbidity and mortality of diabetic patients worldwide. [1][2][3][4] It is estimated that diabetes will reach 366 million by 2030, compared with more than 100 million for diabetic nephropathy. 4,5 According to the data of American Diabetes Association, diabetes mellitus has a major impact on the development of DN.…”

Section: Introductionmentioning

confidence: 99%

A study on the recent 20 years’ herbal medication rules and syndromes distribution in TCM treatment of Diabetic Nephropathy by Data mining

Wang¹,

Song²,

Pan³

et al. 2019

JAH

View full text Add to dashboard Cite

Articles you may be interested in Study of spatial distribution of sandy desertification in North China in recent 10 years Science in China Series DEarth Sciences 47, 78 (2004); Mining API usage change rules for software framework evolution SCIENCE CHINA Information Sciences 61, 050108 (2018); Recent developments in neuropsychological endophenotypes for schizophrenia: Development of the MATRICS battery, liability syndromes and the near future Chinese Science Bulletin 56, 3385 (2011); Sound and complete rules for data reification Science in China Series E-Technological Sciences 40, 379 (1997); Elevated red blood cell distribution width as a marker of higher risk for contrast-induced nephropathy: A systematic review and meta-analysis

show abstract

Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Early-stage chronic kidney disease (CKD) characterized by microalbuminuria is associated with future cardiovascular events, progression toward end-stage renal disease, and early mortality in patients with type 2 diabetes.OBJECTIVE To compare the albuminuria-lowering effects of Roux-en-Y gastric bypass (RYGB) surgery vs best medical treatment in patients with early-stage CKD, type 2 diabetes, and obesity.DESIGN, SETTING, AND PARTICIPANTS For this randomized clinical trial, patients with established type 2 diabetes and microalbuminuria were recruited from a single center from April 1, 2013, through March 31, 2016, with a 5-year follow-up, including prespecified intermediate analysis at 24-month follow-up.INTERVENTION A total of 100 patients with type 2 diabetes, obesity (body mass indexes of 30 to 35 [calculated as weight in kilograms divided by height in meters squared]), and stage G1 to G3 and A2 to A3 CKD (urinary albumin-creatinine ratio [uACR] >30 mg/g and estimated glomerular filtration rate >30 mL/min) were randomized 1:1 to receive best medical treatment (n = 49) or RYGB (n = 51). MAIN OUTCOMES AND MEASURESThe primary outcome was remission of albuminuria (uACR <30 mg/g). Secondary outcomes were CKD remission rate, absolute change in uACR, metabolic control, other microvascular complications, quality of life, and safety.RESULTS A total of 100 patients (mean [SD] age, 51.4 [7.6] years; 55 [55%] male) were randomized: 51 to RYGB and 49 to best medical care. Remission of albuminuria occurred in 55% of patients (95% CI, 39%-70%) after best medical treatment and 82% of patients (95% CI, 72%-93%) after RYGB (P = .006), resulting in CKD remission rates of 48% (95% CI, 32%-64%) after best medical treatment and 82% (95% CI, 72%-92%) after RYGB (P = .002). The geometric mean uACRs were 55% lower after RYGB (10.7 mg/g of creatinine) than after best medical treatment (23.6 mg/g of creatinine) (P < .001). No difference in the rate of serious adverse events was observed. CONCLUSIONS AND RELEVANCEAfter 24 months, RYGB was more effective than best medical treatment for achieving remission of albuminuria and stage G1 to G3 and A2 to A3 CKD in patients with type 2 diabetes and obesity.

show abstract

Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies

Cited by 178 publications

References 145 publications

Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?

Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?

A study on the recent 20 years’ herbal medication rules and syndromes distribution in TCM treatment of Diabetic Nephropathy by Data mining

Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity

Contact Info

Product

Resources

About

Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies

Cited by 178 publications

References 145 publications

Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?

Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?

A study on the recent 20 years&rsquo; herbal medication rules and syndromes distribution in TCM treatment of Diabetic Nephropathy by Data mining

Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity

Contact Info

Product

Resources

About

A study on the recent 20 years’ herbal medication rules and syndromes distribution in TCM treatment of Diabetic Nephropathy by Data mining